title: Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
abstract: Cytomegalovirus (CMV) seronegative renal allograft recipients (R-), particularly those with a graft from a CMV-seropositive donor (D+), are at high risk for primary CMV infection. CMV resistance to antiviral oral therapy is an emerging problem in renal transplantation, prompting development of new prophylactic strategies. We retrospectively studied the 1-year posttransplantation incidence of CMV infection in high-risk renal transplant recipients, in whom polyvalent intravenous immunoglobulins (IVIg) were used as prophylaxis. Forty R- patients received immunoprophylaxis by polyvalent IVIg (0.25 g/kg weekly for 8 weeks, starting on the operative day). CMV serological tests remained negative in eight patients (20%). Eight patients (20%) had asymptomatic CMV infection while 24 (60%) developed CMV syndrome and were treated with gancyclovir (10 mg/kg/day intravenously for 3 weeks). None had CMV disease or opportunistic infection. Six patients (15%) had biopsy-proven acute rejection, which followed CMV syndrome in three cases. One-year renal allograft and patient survivals were 95% and 97.5%, respectively. Mean serum creatinine level was 124 +/- 33 micromol/L at 1 year. Clinical tolerance of IVIg was excellent, without any episode of acute renal failure. Polyvalent IVIg provides effective prophylaxis in renal transplant recipients at high risk for CMV infection and is associated with excellent 1-year allograft survival. Because of their immunomodulatory functions, IVIg may have a beneficial effect on the incidence of acute and chronic rejection and allograft survival. A randomized prospective study is required to evaluate long-term effects of CMV prophylaxis with polyvalent IVIg compared to antiviral agents in renal transplant recipients.
authors.affiliation: Service de Néphrologie, CHU La Milétrie, 86021 Poitiers Cedex, France.
authors.forename: F
authors.initials: F
authors.lastname: Leroy
authors.forename: A
authors.initials: A
authors.lastname: Sechet
authors.forename: R
authors.initials: R
authors.lastname: Abou Ayache
authors.forename: A
authors.initials: A
authors.lastname: Thierry
authors.forename: S
authors.initials: S
authors.lastname: Belmouaz
authors.forename: E
authors.initials: E
authors.lastname: Desport
authors.forename: M
authors.initials: M
authors.lastname: Bauwens
authors.forename: F
authors.initials: F
authors.lastname: Bridoux
authors.forename: G
authors.initials: G
authors.lastname: Touchard
mesh_terms: D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D016030:Kidney Transplantation / Q000276:immunology*; D011183:Postoperative Complications / Q000517:prevention & control; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D016756:Immunoglobulins, Intravenous